Vortioxetine for Treatment of Depressive Mood and Alcohol Use

Inclusion Criteria: * Subjects who are able to understand the study and comply with all study procedures and willing to provide written informed consent prior to screening * Male and female subjects aged 19 to 65 years old * Diagnosed to have major depressive disorder and alcohol use disorder based on DSM(Diagnostic and Statistical Manual of Mental Disorders)-5 by two separate psychiatrists. * MADRS(Montgomery Åsberg Depression Rating Scale) ≥ 26 at baseline Exclusion Criteria: * Subjects considered not safe to participate in the study (e.g. who has suicidal thoughts) * Pregnant or breastfeeding * Subjects with serious or unstable disease * Clinical or laboratory signs of on-going hypothyroidism * History of organic mental disorder, schizophrenia spectrum disorder, bipolar disorder, or substance abuse within 12 months (except for alcohol or nicotine abuse) * Administration of antidepressant (MAOIs, SSRIs, SNRIs, TCAs) including vortioxetine and anti-craving medications (acamprosate, naltrexone) within 2 weeks from screening * Administration of antipsychotic, anti-manic drugs, dopamine antagonists, anxiolytics (zolpidem more than 10mg, Benzodiazepine lorazepam equivalent dosage more than 2mg or used as alcohol withdrawal treatment) within 2 weeks from screening * Administration of anti-depressant, fluoxetine, within 5 weeks from screening * Subjects in need of an alcohol detoxification treatment * Subjects in need of a hospitalization care